Fazpilodemab

Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) [1].

Product Specifications

CAS Number

[2517935-02-1]

Product Name Alternative

BFKB8488A; RG-7992; RO-7040551

UNSPSC

12352203

Target

FGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/fazpilodemab.html

Purity

99.0

Solubility

H2O

Smiles

[Fazpilodemab]

Molecular Weight

(144.48 kDa)

References & Citations

[1]Wong C, et al. Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. Hepatology. 2022 Aug 22.|[2]Baruch A, et al. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans. Proc Natl Acad Sci U S A. 2020 Nov 17;117 (46) :28992-29000.